Celularity to Offer Placenta-Based Stem Cell Therapies in Florida Under New Law
By partnering with Fountain Life, the companies are hoping to deliver new therapies to patients in the sunshine state.
Orthopedics News
Xtant Medical Releases Growth Factor Product to Improve Orthopedic/Spine Surgery Outcomes
OsteoFactor Pro™ targets improved orthopedic healing through enhanced bone regeneration and versatile scaffold compatibility.
BioRestorative reports Good Preliminary Data for FDA-Fast-Tracked Stem Cell Therapy for Disc Disease
BioRestorative's early Phase 2 trial results show notable improvements in function and pain for chronic lumbar disc disease patients, moving one step closer to a BLA.
New trial: Umbilical-derived stem cells for knee cartilage
This small German biotech company is joining the knee OA stem cell race.
New Study: Extracellular Vesicles in Fibrin Gel for Cartilage Repair (Italy)
The Italian researchers will do a 51 person trial with MSC-derived EVs in PRP-derived fibrin gels.
XSTEM’s knee Osteoarthritis stem cell trial: mid-study update, safety and positive efficacy
Interestingly, it appears that the higher the dose, the better the outcome. So far so good... who will win the Knee OA stem cell battle?
Korean Company Launches iPSCs Osteoarthritis Trial
Biotech company YiPSCELL breaks ground on a new trial, will head to safety & efficacy trials soon.
QC Kinetix Increases Standard PRP Dosing to 10 Billion Platelets
They'll roll out the 10B platelet dosing across all 176 locations in the USA, along with blood analysis/patient registry to measure the outcome data. Looking forward to hearing about this.
Joseph Spine Institute Launches Adipose Stem Cell Spine Institute in Florida
Joseph Spine Institute launches its Center for Regenerative Spine Medicine in Tampa, offering minimally invasive stem cell therapies for chronic spinal conditions.
Korea’s ‘JointStem’ Adipose Stem Cell Therapy gets FDA Breakthrough Therapy Designation for Osteoarthritis
Nature Cell Co., Ltd. announced that its cell therapy product, JointStem, has been granted Breakthrough Therapy Designation (BTD) by the U.S. FDA, marking a first for a Korean company in this field. This designation is expected to expedite the development and approval process of JointStem,…
MEDIPOST’s stem cell therapy regenerates stronger cartilage than microdrilling, clears path to US phase 3
Recent clinical data presented at the AAOS 2025 Annual Meeting in San Diego suggest that MEDIPOST's stem cell therapy, Cartistem, may offer a more effective treatment for severe knee osteoarthritis (OA) compared to traditional microdrilling techniques. The study tracked 25…
New rotator cuff repair tech: Atreon Orthopedics gets FDA 510(k) clearance and full market launch of BioCharge® Autobiologic Matrix
Colombus-based Atreon Orthopedics says they've received 510(k) clearance from the FDA for its BioCharge® Autobiologic Matrix. This bioresorbable synthetic implant is designed to address biological failure modes in rotator cuff repair, potentially improving repair integrity and long-term patient outcomes. Image…
Case Series: Wharton’s Jelly for Neuropathy from Tarsal Tunnel
Link to study, found in the journal named Reports, dated 2024. The problem? Neuropathy of the lower leg caused by tarsal tunnel syndrome Symptoms include Sharp shooting pain Pins/needles Electric shock/burning sensations Credit Healthline.com The treatment studied? Wharton’s Jelly injected…
Study: Expanded Wharton’s Jelly for Knee Osteoarthritis with Before/After MRI Data
Link to study, found in the Regenerative Medicine Journal, dated August 2021. The problem? Knee osteoarthritis The treatment studied? 2 injections of 40 million expanded (passage 3) Wharton's Jelly mesenchymal stem cells Ultrasound guidance injection into the knee joint, 1…
BioRestorative Therapies nabs FDA IND clearance for Phase 2 trial of its autologous cultured mesenchymal stem cell therapy, ‘BRTX-100″ for spine conditions
BioRestorative Therapies, a regenerative medicine company focused on stem cell-based therapies, has announced that the FDA has cleared its Investigational New Drug (“IND”) application for BRTX-100, a novel cell-based therapeutic engineered to target areas of the body that have little…